Back to Search
JAMES ZWIEBEL, M.D.
Hematology & Oncology Physician
NPI: 1366868622Individual
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
D0025198(MD)
Research & Publications (20)
A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer.
PMID 19383814·Clin Cancer Res·2009
3-trial
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.
PMID 19671864·Clin Cancer Res·2009
3-trial
Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.
PMID 18854394·J Clin Endocrinol Metab·2009
3-trial
Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer.
PMID 19225720·Invest New Drugs·2009
3-trial
Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.
PMID 19307505·J Clin Oncol·2009
3-trial
G3139 (Genasense) in patients with advanced merkel cell carcinoma.
PMID 19307957·Am J Clin Oncol·2009
3-trial
Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer.
PMID 19047121·Clin Cancer Res·2008
3-trial
A phase I-II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798).
PMID 18060598·Invest New Drugs·2008
3-trial
A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors.
PMID 18451239·Clin Cancer Res·2008
3-trial
Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.
PMID 18559610·Clin Cancer Res·2008
3-trial
Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma.
PMID 18764869·Br J Haematol·2008
3-trial
Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.
PMID 17510206·Clin Cancer Res·2007
3-trial
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.
PMID 17179232·Blood·2007
3-trial
Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study.
PMID 17442993·J Clin Oncol·2007
3-trial
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies.
PMID 17875771·Clin Cancer Res·2007
3-trial
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.
PMID 16778214·Cancer Res·2006
8-other
Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301.
PMID 16849749·J Clin Oncol·2006
3-trial
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
PMID 15851766·J Clin Oncol·2005
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 9609 MEDICAL CENTER DR, ROOM 5W-460, MSC 9739
BETHESDA, MD 20892 - Phone
- (240) 276-6565
Quick Facts
- NPI
- 1366868622
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile